THE INVESTOR

메뉴열기
June 24, 2019

Syntekabio gears up for IPO this year

PUBLISHED : May 20, 2019 - 14:56

UPDATED : May 20, 2019 - 14:56

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

Korean new drug developer Syntekabio is preparing to go public, after receiving approval for a drug candidate from CJ Healthcare, according to industry sources on May 20.

The company has picked KB Securities as its IPO manager. Syntekabio is hoping to go public before the year-end but declined to explain plan details, saying nothing has been decided yet.




Established in 2009, the firm mainly focuses on developing technology for analyzing patients’ genome using big data and personal genome maps. Additionally, is trying to combine genome big data platform with artificial intelligence technology to utilize it for developing new drugs.

In March, Syntekabio received a pipeline for cancer treatment, which it was co-developing with CJ Healthcare. According to sources, securing it boosted its possibility of a successful IPO.

Syntekabio is expanding its business by cooperating with other local pharma giants including JW Pharmaceutical. Its sales last year reached 300 million won ($252,450) while posting 3 billion won in operating profit.

Currently, Syntekabio founder and CEO Jung Joong-sun is the largest shareholder with 25.48 percent stake.

By Song Seung-hyun (ssh@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Yang Sung-jin
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. 아 04099
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.